CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.
  
  LEARNING OBJECTIVES

  • Evaluate published research data to guide the selection and duration of neoadjuvant, adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for newly diagnosed ER-positive breast cancer.
  • Consider available clinical trial findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the optimal role of these agents as neoadjuvant or adjuvant treatment.
  • Appreciate available Phase III data documenting the efficacy of adjuvant PARP inhibition for patients with high-risk HER2-negative localized breast cancer and BRCA mutations, and consider the role of this strategy in clinical practice.
  • Review published research data supporting the benefit of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for patients with localized triple-negative breast cancer (TNBC), and use this information to make appropriate treatment recommendations.
  • Implement a long-term clinical plan for the care of patients with metastatic HER2-positive breast cancer, incorporating existing and recently approved anti-HER2 therapies.
  • Individualize the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer, considering age, menopausal status, prior treatment course, PIK3CA mutation status, comorbidities, symptomatology and extent and sites of disease.
  • Evaluate published research findings guiding the selection and sequencing of available therapeutic agents for patients with metastatic TNBC.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic breast cancer harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Assess the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for localized and metastatic breast cancer.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Joyce O’Shaughnessy, MD
  Celebrating Women Chair in Breast Cancer Research
  Baylor University Medical Center
  Director, Breast Cancer Research Program
  Texas Oncology
  US Oncology
  Dallas, Texas
  
  Advisory Committee and Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Athenex, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Carrick Therapeutics, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Ontada, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sandoz Inc, a Novartis Division, Sanofi, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Theralink; Nonrelevant Financial Relationship: prIME Oncology.
  
  Professor Peter Schmid, FRCP, MD, PhD
  Director, Breast Centre
  Barts Hospital
  Professor of Cancer Medicine
  Barts Cancer Institute
  London, United Kingdom
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Lilly, Merck, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research/Research Support (to Institution): Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GSK, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Merck, and Seagen Inc.
  
  Release date: January 2023
  Expiration date: January 2024